Stockreport

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc.  (TNGX) 
PDF Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust [Read more]